NO20060080L - Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer - Google Patents

Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer

Info

Publication number
NO20060080L
NO20060080L NO20060080A NO20060080A NO20060080L NO 20060080 L NO20060080 L NO 20060080L NO 20060080 A NO20060080 A NO 20060080A NO 20060080 A NO20060080 A NO 20060080A NO 20060080 L NO20060080 L NO 20060080L
Authority
NO
Norway
Prior art keywords
liver
dition
pyrrole
derivatives
receptor modulators
Prior art date
Application number
NO20060080A
Other languages
English (en)
Norwegian (no)
Inventor
Patrik Holm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20060080L publication Critical patent/NO20060080L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20060080A 2003-07-11 2006-01-05 Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer NO20060080L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316237.7A GB0316237D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
PCT/SE2004/001115 WO2005005416A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators

Publications (1)

Publication Number Publication Date
NO20060080L true NO20060080L (no) 2006-02-08

Family

ID=27741986

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060080A NO20060080L (no) 2003-07-11 2006-01-05 Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer

Country Status (25)

Country Link
US (1) US20060189663A1 (enExample)
EP (1) EP1646625B1 (enExample)
JP (1) JP2007521313A (enExample)
KR (1) KR20060034284A (enExample)
CN (1) CN100478340C (enExample)
AR (1) AR045720A1 (enExample)
AT (1) ATE399776T1 (enExample)
AU (1) AU2004256000B2 (enExample)
BR (1) BRPI0412479A (enExample)
CA (1) CA2532068A1 (enExample)
CO (1) CO5640134A2 (enExample)
DE (1) DE602004014772D1 (enExample)
ES (1) ES2308205T3 (enExample)
GB (1) GB0316237D0 (enExample)
IL (1) IL172759A0 (enExample)
IS (1) IS8291A (enExample)
MX (1) MXPA06000447A (enExample)
NO (1) NO20060080L (enExample)
RU (1) RU2006102129A (enExample)
SA (1) SA04250203B1 (enExample)
TW (1) TW200507836A (enExample)
UA (1) UA82108C2 (enExample)
UY (1) UY28407A1 (enExample)
WO (1) WO2005005416A1 (enExample)
ZA (1) ZA200600229B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582629B2 (en) 2005-01-10 2009-09-01 Astrazeneca Ab Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
WO2007002654A2 (en) * 2005-06-28 2007-01-04 Daiichi Sankyo Company, Limited. Lxr ligand testing method
EP2069359B1 (en) 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
US20100056444A1 (en) 2006-10-12 2010-03-04 Sven Martin Jacobson Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
US20100143270A1 (en) * 2007-02-21 2010-06-10 University Of Louisville Research Foubdation Therapeutic cotinine compositions
WO2009073711A1 (en) 2007-12-04 2009-06-11 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
WO2009097443A2 (en) * 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
CA2727252A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Isoindolone derivatives as mek kinase inhibitors and methods of use
PE20110570A1 (es) 2008-07-01 2011-08-26 Genentech Inc Heterociclos biciclicos sustituidos
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
CN109069461A (zh) 2016-01-11 2018-12-21 洛克菲勒大学 与髓源性抑制细胞相关的病症的治疗方法
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
KR200492570Y1 (ko) 2018-12-04 2020-11-05 박규환 조립식 계단장치를 위한 발판
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69922526T2 (de) * 1998-10-08 2005-06-02 Smithkline Beecham Plc, Brentford 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
CA2377999A1 (en) * 1999-07-08 2001-01-18 Tularik Inc Compositions and methods for raising hdl cholesterol levels

Also Published As

Publication number Publication date
CA2532068A1 (en) 2005-01-20
ES2308205T3 (es) 2008-12-01
ZA200600229B (en) 2007-04-25
UY28407A1 (es) 2005-02-28
SA04250203B1 (ar) 2008-02-25
CO5640134A2 (es) 2006-05-31
EP1646625B1 (en) 2008-07-02
DE602004014772D1 (de) 2008-08-14
AR045720A1 (es) 2005-11-09
HK1088318A1 (en) 2006-11-03
EP1646625A1 (en) 2006-04-19
BRPI0412479A (pt) 2006-09-19
AU2004256000B2 (en) 2007-07-26
CN100478340C (zh) 2009-04-15
MXPA06000447A (es) 2006-04-07
WO2005005416A1 (en) 2005-01-20
GB0316237D0 (en) 2003-08-13
KR20060034284A (ko) 2006-04-21
AU2004256000A1 (en) 2005-01-20
JP2007521313A (ja) 2007-08-02
IL172759A0 (en) 2006-04-10
TW200507836A (en) 2005-03-01
US20060189663A1 (en) 2006-08-24
CN1820003A (zh) 2006-08-16
IS8291A (is) 2006-02-09
UA82108C2 (uk) 2008-03-11
RU2006102129A (ru) 2006-08-27
ATE399776T1 (de) 2008-07-15

Similar Documents

Publication Publication Date Title
NO20060080L (no) Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer
NO20073250L (no) Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.
NO20060081L (no) Pyrrol-2,5-dionderivater som lever X reseptormodulatorer
ES2257757T3 (es) Carboxilato de terfenadina y el tratamiento de trastornos alergicos.
NO20055892L (no) Karboksylsyrederivater
WO2007050726A3 (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
EP4537816A3 (en) Treatment of type-2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
WO2009009501A3 (en) Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
NO20073248L (no) Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer
BRPI0516237A (pt) derivado de pirimidina fundido com anel não aromático
CN102093246B (zh) 酯类化合物、其制备方法和应用
CN103462886B (zh) 稳定的左乙拉西坦注射液
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
WO2008131469A3 (de) Verfahren zur herstellung von hoch reinem 2,4 '-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
Al-Masri et al. Antidiabetic effect of flavonoid from Rumex vesicarius on alloxan induced diabetes in male albino Wistar rats and its validation through in silico molecular docking and dynamic simulation studies
CN103040779A (zh) 用于神经系统疾病的口服固体药物组合物
EP1435353A1 (en) Novel heterocyclic compound and anti-inflammatory agent
NO20065501L (no) Lxr reseptor modulstorer.
SE0500056D0 (sv) Therapeutic agents 4
EP2412705B1 (en) Novel therapeutic agent for cognitive impairment
SE0500058D0 (sv) Therapeutic agents 5
US5087628A (en) 4,4'-[9H-fluoren-9-ylidenebis (methylene)]bispyrimidine for treating neurological disorders
CN104523712B (zh) 一种盐酸吡格列酮格列美脲片剂组合物

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application